Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Neuroendocrine Prostate Cancer Market Growth From $1.14 Billion In 2026 To $1.6 Billion By 2030 At A CAGR Of 8.7%
The market size for neuroendocrine prostate cancer has demonstrated robust growth in recent years. Projections indicate it will expand from $1.05 billion in 2025 to $1.14 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.5%. Historically, this expansion can be ascribed to several factors, including an increase in prostate cancer diagnosis, the development of long term hormone therapy resistance, the broadening of oncology drug pipelines, the proliferation of molecular pathology testing, and enhanced cancer center specialization.
The neuroendocrine prostate cancer market is projected for robust expansion over the coming years, reaching $1.6 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. This anticipated growth during the forecast period is fueled by the increased adoption of precision oncology, the rise of biomarker-based treatments, the broader availability of targeted therapies, enhanced funding for rare cancer research, and wider utilization of genomic testing. Key trends emerging in this period encompass biomarker-driven patient stratification, the implementation of combination oncology therapy protocols, advancements in molecular diagnostic testing, the broadening of rare cancer clinical trials, and the development of targeted radiopharmaceutical strategies.
Get A Free Sample Report With In-Depth Market Insights:
Neuroendocrine Prostate Cancer Market Expansion Drivers: What’s Shaping Future Growth?
The rising incidence of prostate cancer is anticipated to fuel the expansion of the neuroendocrine prostate cancer market in the coming years. Prostate cancer constitutes a cancerous growth originating in the prostate gland, predominantly affecting males aged 50 and above. The increasing occurrence of prostate cancer is largely attributable to the expanding elderly male demographic, given that older age represents a significant risk factor for the condition’s onset. The widespread presence of prostate cancer contributes to the growth of neuroendocrine prostate cancer by enlarging the total number of patients, prolonging exposure to androgen-deprivation treatments, and thereby elevating the probability of developing treatment-induced neuroendocrine differentiation in later and castration-resistant phases of the disease. For example, the Centers for Disease Control and Prevention (CDC), a U.S. federal public health agency, indicated in January 2025 that 2023 saw 255,395 new diagnoses of prostate cancer within the United States, alongside 33,881 male fatalities attributed to the condition. Consequently, the growing incidence of prostate cancer is a key driver for the neuroendocrine prostate cancer market’s expansion.
Neuroendocrine Prostate Cancer Market Segment Analysis: What Are The Core Market Categories?
The neuroendocrine prostate cancer market covered in this report is segmented –
1) By Treatment: Chemotherapy; Hormonal Therapy
2) By Therapeutics: Immunotherapy; Targeted Therapy
3) By Disease Stage: Localized Disease; Advanced Disease; Metastatic Disease
4) By End Users: Hospitals; Oncology Specialty Clinics; Cancer Research Institutes
Subsegments:
1) By Chemotherapy: Platinum Based Chemotherapy; Taxane Based Chemotherapy; Combination Chemotherapy; Second Line Chemotherapy
2) By Hormonal Therapy: Androgen Deprivation Therapy; Androgen Receptor Inhibition; Hormone Synthesis Inhibition; Combined Hormonal Therapy
Neuroendocrine Prostate Cancer Market Strategic Trends: What Defines The Next Growth Phase?
Leading companies operating in the neuroendocrine prostate cancer market are concentrating on developing innovative drugs, such as immune-modulating small-molecule therapies, to enhance immune response and improve patient outcomes. These orally administered compounds function by stimulating the body’s innate immune system to recognize and attack cancer cells, thereby helping overcome resistance to traditional treatments like hormone therapy or chemotherapy by bolstering the anti-tumor immune response. For instance, in February 2024, BioXcel Therapeutics, a US-based clinical-stage biopharmaceutical company, was granted Fast Track Designation by the U.S. Food and Drug Administration for BXCL701, an immune-modulating small-molecule therapy specifically for neuroendocrine prostate cancer. BXCL701 is engineered to activate the NLRP3 inflammasome, increase cytokine release, and prime the immune system to target tumor cells, offering a novel method that complements immune checkpoint inhibitors. This Fast Track Designation is expected to accelerate the clinical development and regulatory review of BXCL701, reflecting its capacity to address significant unmet medical needs in aggressive and treatment-resistant prostate cancer.
Neuroendocrine Prostate Cancer Market Leading Companies And Competitive Benchmarking
Major companies operating in the neuroendocrine prostate cancer market are Novartis AG, Amgen Inc., Phanes Therapeutics Inc., and BioXcel Therapeutics Inc.
View The Full Neuroendocrine Prostate Cancer Market Report:
Neuroendocrine Prostate Cancer Market Largest Region By Revenue And Market Share
North America was the largest region in the neuroendocrine prostate cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroendocrine prostate cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
